Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Bemdaneprocel

Source date not recordedAnalyse record ↗

Allogeneic dopaminergic-neuron progenitor therapy in a pivotal Phase 3 trial for Parkinson's disease.

Modality
allogeneic pluripotent-stem-cell-derived dopaminergic neuron progenitor therapy
Availability (US)
Recruiting Phase 3 exPDite-2; first randomized participant treated September 22, 2025; investigational and not approved
Biomarkers
dopaminergic cell survival and engraftment imaging; motor function; quality of life; safety and tolerability
Hallmark targeted
stem-cell exhaustion, loss of regenerative capacity, neurodegeneration
Kind
investigational cell therapy
Clinical trials
NCT06944522 — exPDite-2 randomized, double-blind, sham-surgery-controlled Phase 3 study in Parkinson's disease